AU2000239309A1 - Insulin and igf-1 receptor agonists and antagonists - Google Patents

Insulin and igf-1 receptor agonists and antagonists

Info

Publication number
AU2000239309A1
AU2000239309A1 AU2000239309A AU3930900A AU2000239309A1 AU 2000239309 A1 AU2000239309 A1 AU 2000239309A1 AU 2000239309 A AU2000239309 A AU 2000239309A AU 3930900 A AU3930900 A AU 3930900A AU 2000239309 A1 AU2000239309 A1 AU 2000239309A1
Authority
AU
Australia
Prior art keywords
insulin
antagonists
peptides
igf
therapeutics
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2000239309A
Inventor
James Beasley
Arthur J Blume
Jakob Brandt
Renee Brissette
Weiqing Cheng
Per Hertz Hansen
Ku-Chuan Hsiao
Wlodek S. Mandecki
Soren Ostergaard
Renuka Pillutla
Mark Ravera
Lauge Schaffer
Jane Spetzler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
DGI BioTechnologies LLC
Original Assignee
Novo Nordisk AS
DGI BioTechnologies LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS, DGI BioTechnologies LLC filed Critical Novo Nordisk AS
Publication of AU2000239309A1 publication Critical patent/AU2000239309A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/65—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Abstract

Peptide sequences capable of binding to insulin and/or insulin-like growth factor receptors with either agonist or antagonist activity and identified from various peptide libraries are disclosed. This invention also identifies at least two different binding sites which are present on insulin and insulin-like growth factor receptors which selectively bind the peptides of this invention. As agonists, certain of the peptides of this invention may be useful for development as therapeutics to supplement or replace endogenous peptide hormones. The antagonists may also be developed as therapeutics. In one embodiment, the receptor-binding peptides comprise the core motive B6: X 6 X 7 X 8 X 9 X 10 X 11 X 12 X 13 wherein X 6 and X 7 are aromatic, and X 10 and X 13 are hydrophobic residues.
AU2000239309A 2000-03-29 2000-03-29 Insulin and igf-1 receptor agonists and antagonists Abandoned AU2000239309A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2000/008528 WO2001072771A2 (en) 2000-03-29 2000-03-29 Insulin and igf-1 receptor agonists and antagonists

Publications (1)

Publication Number Publication Date
AU2000239309A1 true AU2000239309A1 (en) 2001-10-08

Family

ID=21741219

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2000239309A Abandoned AU2000239309A1 (en) 2000-03-29 2000-03-29 Insulin and igf-1 receptor agonists and antagonists

Country Status (6)

Country Link
EP (2) EP1383793B1 (en)
JP (1) JP2004512010A (en)
AT (1) ATE529435T1 (en)
AU (1) AU2000239309A1 (en)
CA (1) CA2402780A1 (en)
WO (1) WO2001072771A2 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
US6875741B2 (en) * 1998-09-02 2005-04-05 Renuka Pillutla Insulin and IGF-1 receptor agonists and antagonists
ATE389416T1 (en) 2000-05-16 2008-04-15 Genentech Inc TREATMENT OF CARTILARY DISEASES
ES2278020T3 (en) 2001-02-09 2007-08-01 Genentech, Inc. CRYSTALLIZATION OF IGF-1.
CA2439735A1 (en) 2001-03-14 2002-09-19 Genentech, Inc. Igf antagonist peptides
IL164376A0 (en) * 2002-04-03 2005-12-18 Applied Research Systems Ox4or binding agents, their preparation and pharmaceutical compositions containing them
PL210412B1 (en) 2002-05-24 2012-01-31 Schering Corp Neutralizing human anti-igfr antibody
CA2490280A1 (en) 2002-07-01 2004-01-08 Human Genome Sciences, Inc. Antibodies that specifically bind to reg iv
KR20120060250A (en) * 2002-12-20 2012-06-11 암겐 인코포레이티드 Binding agents which inhibit myostatin
US7192738B2 (en) 2003-10-03 2007-03-20 Genentech, Inc. IGF binding proteins
CN1938428A (en) 2003-11-12 2007-03-28 先灵公司 Plasmid system for multigene expression
EP1812082B1 (en) * 2004-10-21 2013-08-14 IGF Oncology, LLC Toxins and radionuclides coupled to IGF-1 receptor ligands for the treatment of cancer
EP2283831A3 (en) 2004-12-03 2013-10-23 Merck Sharp & Dohme Corp. Biomakers for pre-selection of patients for anti-IGF1R therapy
EP2333067A1 (en) 2005-03-25 2011-06-15 National Research Council of Canada Method for isolation of soluble polypeptides
CA2650656A1 (en) * 2005-05-05 2007-01-11 Valorisation Hsj, Societe En Commandite Cytokine receptor modulators and uses thereof
US7659362B2 (en) * 2006-05-30 2010-02-09 Academia Sinica Metal-binding motif compositions and methods
AU2008244496A1 (en) 2007-04-24 2008-11-06 Antyra Inc. IGF-1R binding proteins and antagonists
US20100316639A1 (en) 2009-06-16 2010-12-16 Genentech, Inc. Biomarkers for igf-1r inhibitor therapy
JP2014156401A (en) * 2011-05-25 2014-08-28 Hoya Corp Igf-1r-binding peptide
CN111377773A (en) * 2020-04-16 2020-07-07 山东省现代中药研究院有限公司 Seaweed compound microbial organic fertilizer containing endophytes and used for peanuts

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4963665A (en) * 1986-01-07 1990-10-16 Washington University Human preproinsulin-like growth factor I
US4876242A (en) * 1987-09-21 1989-10-24 Merck & Co., Inc. Human insulin-like growth factor analoges with reduced binding to serum carrier proteins and their production in yeast
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
US6010861A (en) 1994-08-03 2000-01-04 Dgi Biotechnologies, Llc Target specific screens and their use for discovering small organic molecular pharmacophores
DE4432943A1 (en) * 1994-09-15 1996-03-21 Radulescu Razvan T Dr Med M D Selection of peptide(s) with high binding affinity for target protein
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
JPH11506722A (en) * 1995-06-07 1999-06-15 ベイラー・カレッジ・オブ・メディスン Nucleic acid carriers for delivering nucleic acids to cells
RU2078769C1 (en) * 1995-08-18 1997-05-10 Научно-исследовательский институт биомедицинской химии РАМН Peptide fragment showing biological activity of insulin
US5912160A (en) * 1995-08-22 1999-06-15 Thomas Jefferson University Gab1, Grb2 binding protein, and compositions for making and methods of using the same
AU3568697A (en) * 1996-06-07 1998-01-05 Genetics Institute Inc. Polynucleotides from human adult pbmc endocing secreted proteins
EP0960335B1 (en) * 1997-01-15 2005-05-25 Telik, Inc. Modulators of insulin receptor activity
US6413517B1 (en) * 1997-01-23 2002-07-02 Epimmune, Inc. Identification of broadly reactive DR restricted epitopes
WO1999028347A1 (en) * 1997-11-27 1999-06-10 Commonwealth Scientific And Industrial Research Organisation Method of designing agonists and antagonists to igf receptor
AU2321999A (en) * 1998-01-16 1999-08-02 Genzyme Corporation Adenoviral vectors with modified capsid proteins
IL140918A0 (en) * 1998-07-27 2002-02-10 Genentech Inc Improved transformation efficiency in phage display through modification of a coat protein

Also Published As

Publication number Publication date
ATE529435T1 (en) 2011-11-15
JP2004512010A (en) 2004-04-22
EP2368902A2 (en) 2011-09-28
WO2001072771A3 (en) 2003-12-04
EP1383793A2 (en) 2004-01-28
EP2368902A3 (en) 2011-12-21
CA2402780A1 (en) 2001-10-04
WO2001072771A2 (en) 2001-10-04
EP1383793B1 (en) 2011-10-19

Similar Documents

Publication Publication Date Title
AU2000239309A1 (en) Insulin and igf-1 receptor agonists and antagonists
WO2003070747A3 (en) Insulin and igf-1 receptor agonists and antagonists
PT2241575E (en) Igf-1 fusion polypeptides and therapeutic uses thereof
WO2002072780A3 (en) Igf antagonist peptides
WO2003040309A3 (en) Peptides acting as both glp-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use
AU2003242352A1 (en) Adiponectin receptor and gene coding for the same
MA31242B1 (en) Co-agonists for glycagon receptors
EP1251137A3 (en) Use of insulin-like growth factor agonist peptides
AU5716901A (en) G protein coupled receptor (gpcr) agonists and antagonists and methods of activating and inhibiting gpcr using the same
WO1999060119A3 (en) Multivalent t cell receptor complexes
WO2000018932A3 (en) Receptor based antagonists and methods of making and using
MX9700822A (en) Cosmetic composition containing a neuropeptide y receptors antagonist.
IL181311A (en) Polypeptide variants of neublastin, dimers, conjugates and fusion proteins comprising them, pharmaceutical compositions based thereupon, nucleic acids encoding them, expression vectors comprising the nucleic acids, cells comprising said vectors, methods for making and uses of said polypeptides
ATE235687T1 (en) PEPTIDES WITH SPECIFIC AFFINITY FOR PACAP TYPE 1 RECEPTORS
WO2002102839A3 (en) Novel g-protein coupled receptors and dna sequences thereof
ES2129120T3 (en) A RECEPTOR OF HUMAN T CELLS FROM THE FAMILY OF RECEPTORS COUPLED TO PROTEIN G.
Land et al. Assay for galanin receptor
Abribat et al. Characterization of [125I-Tyr10] human growth hormone-releasing factor (1–44) amide binding to rat pituitary: evidence for high and low affinity classes of sites
WO2001049847A3 (en) 26904, 38911, and 39404, seven-transmembrane proteins/g-protein coupled receptors
WO2003012053A3 (en) Identification of receptor and heparin binding sites in fgf4 by structure-based mutagenesis
WO2000050563A3 (en) G protein-coupled receptor resembling galanin receptors
WO2005075021A3 (en) Chemically-modified human growth hormone receptor antagonist conjugates
DE69936638D1 (en) IGF-CONTAINING INJECTABLE FORMULATIONS INCLUDED SUCCINATE AS BUFFER
WO2004091550A3 (en) Compositions and methods for delivering thymosin beta 4, analogues, isoforms and other derivatives
ATE466880T1 (en) CYTOKINE POLYPEPTIDE VARIANTS